To investigate the oncogenic process of SLC3A2 in NPC, we analyzed a cohort of 88 patients from GSE102349 and divided them into low SLC3A2 expression (n = 62) and high SLC3A2 expression (n = 26) groups. This evidence concerns the gene SLC3A2 and nasopharyngeal carcinoma.